As of 2025-07-07, the Relative Valuation of Reyon Pharmaceutical Co Ltd (102460.KS) is 3,976.69 KRW. This relative valuation is based on P/E multiples. With the latest stock price at 11,790.00 KRW, the upside of Reyon Pharmaceutical Co Ltd based on Relative Valuation is -66.3%.
The range of the Relative Valuation is 1,965.15 - 6,153.71 KRW.
| Range | Selected | |
| Trailing P/E multiples | 9.0x - 15.5x | 11.5x |
| Forward P/E multiples | 10.7x - 14.5x | 12.8x |
| Fair Price | 1,965.15 - 6,153.71 | 3,976.69 |
| Upside | -83.3% - -47.8% | -66.3% |
| Date | P/E |
| 2025-05-09 | 50.33 |
| 2025-05-08 | 50.33 |
| 2025-05-07 | 50.79 |
| 2025-05-02 | 51.57 |
| 2025-04-30 | 52.26 |
| 2025-04-29 | 52.67 |
| 2025-04-28 | 52.44 |
| 2025-04-25 | 52.58 |
| 2025-04-24 | 52.21 |
| 2025-04-23 | 52.21 |
| 2025-04-22 | 51.48 |
| 2025-04-21 | 51.29 |
| 2025-04-18 | 51.52 |
| 2025-04-17 | 51.52 |
| 2025-04-16 | 50.23 |
| 2025-04-15 | 50.65 |
| 2025-04-14 | 50.97 |
| 2025-04-11 | 50.23 |
| 2025-04-10 | 48.67 |
| 2025-04-09 | 46.65 |
| 2025-04-08 | 46.23 |
| 2025-04-07 | 46.32 |
| 2025-04-04 | 49.18 |
| 2025-04-03 | 48.35 |
| 2025-04-02 | 50.14 |
| 2025-04-01 | 51.61 |
| 2025-03-31 | 51.57 |
| 2025-03-28 | 53.32 |
| 2025-03-27 | 54.10 |
| 2025-03-26 | 54.47 |
| 2025-03-25 | 54.42 |
| 2025-03-24 | 53.82 |
| 2025-03-21 | 54.74 |
| 2025-03-20 | 53.78 |
| 2025-03-19 | 54.14 |
| 2025-03-18 | 54.33 |
| 2025-03-17 | 54.28 |
| 2025-03-14 | 54.19 |
| 2025-03-13 | 54.05 |
| 2025-03-12 | 54.51 |
| 2025-03-11 | 53.96 |
| 2025-03-10 | 54.37 |
| 2025-03-07 | 54.42 |
| 2025-03-06 | 55.57 |
| 2025-03-05 | 55.57 |
| 2025-03-04 | 54.60 |
| 2025-02-28 | 54.93 |
| 2025-02-27 | 57.41 |
| 2025-02-26 | 58.38 |
| 2025-02-25 | 58.47 |